8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE (INCB123667) for Ovarian cancer

Inclusion criteria

• {"criterion_text":"- 1. Ability to comprehend and willingness to sign a written ICF for the study.\n- 10. Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds. Medical exceptions include: active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring (eg, uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision).\n- 11. Have had documented disease progression during or after their last line of anticancer therapy prior to study entry.\n- 12. Measurable disease per RECIST v1.1 on CT or MRI. Note the following: • Lesions situated in a previously irradiated field are considered measurable if progression has subsequently been demonstrated. • Tumor lesions that have been biopsied should not be selected as target lesions unless post-biopsy imaging confirms that it still qualifies as a RECIST-defined measurable lesion.\n- 13. Ability to take medication orally.\n- 14. ECOG performance status of 0 or 1 (see Table 23 in the Protocol).\n- 15. Willingness to avoid pregnancy based on the criteria below. a. Female participants who are WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose of INCB123667, paclitaxel, gemcitabine, or topotecan, and 240 days after the last dose of PLD and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) and refrain from donating oocytes from screening through 180 days after the last dose of study treatment. Permitted methods in preventing pregnancy (see Appendix A in the Protocol) should be communicated to the participants and their understanding confirmed. b. Female participants not considered to be of childbearing potential as defined in Appendix A in the Protocol are eligible.\n- 2. Female participants aged 18 years or older at the time of signing the ICF (in France, participants should be aged 18 to 99 years, inclusive, at the time of signing the ICF).\n- 3. Willingness and ability to conform to and comply with all Protocol requirements, including all scheduled visits and Protocol procedures.\n- 4. Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.\n- 5. Have platinum-resistant disease. a. Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum-containing regimen, had a response (CR or PR) or had non-measurable disease at the start of platinum-based therapy, and then progressed between > 3 months and ≤ 6 months after the last dose of platinum. b. Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.\n- 6. Willingness to provide archival tumor tissue or, if not available or inadequate, undergo a fresh pretreatment biopsy. Note: An archival FFPE tumor tissue block or slides collected within 5 years prior to signing the prescreening ICF is acceptable\n- 7. Tumor FRα expression level must be known (see also Section 8.5.3 in the Protocol).\n- 8. Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent chemotherapy is considered an appropriate next therapeutic option. Points to consider when determining the number of therapies received: • Neoadjuvant systemic therapy followed by postoperative adjuvant therapy will be considered as 1 line of therapy. • Maintenance therapy (eg, bevacizumab or PARP inhibitors) will not be considered as a separate line of therapy. • Hormonal therapy will not be considered as a separate line of therapy. • Therapy changes due to toxicity in the absence of disease progression will not be considered as a separate line of therapy.\n- 9. Should have received prior treatment with bevacizumab unless there was a contraindication for its use."}

Exclusion criteria

• {"criterion_text":"- 1.\tHave endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.\n- 18. Any radiation therapy within 14 days before the first dose of study treatment. Note: Radiation-related toxicities must have improved to ≤ Grade 1.\n- 19. Current treatment with another investigational medication or having been treated with an investigational medication other than the study treatment within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n- 2. Have primary platinum-refractory disease, defined as progression on or within 3 months after the last dose of first-line platinum-containing therapy.\n- 20. Current use of prohibited medication as described in Section 6.6.3 in the Protocol.\n- 21. For participants assigned to receive INCB123667 only: current treatment with any strong CYP3A4/CYP3A5 inhibitor or inducer (Appendix G in the Protocol) or having been treated with a strong tYP3A4/CYP3A5 inhibitor or inducer within 5 half-lives or 28 days (whichever is shorter) before the first dose of INCB123667.\n- 22. Known history of HBV infection with detectable HBV DNA. In cases of chronic HBV infection with active disease, HBV DNA ≥ 500 IU/mL during screening is exclusionary. Additionally, these participants are also excluded if they: • have not been on anti-HBV treatment (per local practice) for a minimum of 14 days before the first dose of study treatment, and • are not willing to continue on anti-HBV treatment during the study.\n- 23. Known history of HCV infection with detectable HCV RNA. Note: Participants who have completed treatment for HCV and are HCV RNA negative are eligible.\n- 24. Known history of HIV infection and any of the following: • CD4+ T-cell count < 350 cells/µL, • Detectable HIV RNA, or • On an ART regimen containing drugs that are strong CYP3A4/CYP3A5 inhibitors or inducers. Note: Switching to an alternative ART regimen with drugs that are weak or moderate CYP3A4/CYP3A5 inhibitors or inducers is allowed but must be taken for at least 28 days before the first dose of study treatment.\n- 25. Any other infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment within 1 week before the first dose of study treatment.\n- 26. For participants assigned to receive PLD only: previous clinical diagnosis of noninfectious ILD, including noninfectious pneumonitis.\n- 10. Clinically significant gastrointestinal abnormality, including the following: a. Hospitalization for or clinical findings consistent with a gastrointestinal obstruction within 3 months of signing the main ICF or radiographic evidence of gastrointestinal obstruction at the time of screening. Gastrointestinal obstruction from an uncomplicated isolated lesion that has resolved following primary resection within 3 months of consent may be considered on a case-by-case basis in consultation with the medical monitor to determine suitability for participation. b. Ascites requiring paracentesis more often than every 4 weeks for symptomatic management. Enrollment of participants with an indwelling peritoneal catheter may be considered in consultation with the medical monitor to determine suitability for participation. c. Abdominal/pelvic fistula that still requires active management.. d. Requirement for enteral or parenteral nutrition. e. Malabsorption syndromes and prior surgical procedures that might affect the gastrointestinal transit and absorption of orally taken medication. f. Known endoscopically-determined active gastroduodenal ulcer(s). g. Gastrointestinal bleeding (e.g. hematemesis, hematochezia, and melena) within 3 months before the first dose of study treatment.\n- 27. Known hypersensitivity or severe reaction to any component of study drug(s)/treatment or formulation components.\n- 28. Women who are pregnant (including women who may possibly be pregnant based on medical interview by investigators in Japan), breastfeeding, or expecting to conceive, starting with the screening visit through 180 days after the last dose of INCB123667, paclitaxel, gemcitabine or topotecan, and 240 days after the last dose of PLD. For Japan, women who are breastfeeding and wish to enroll must discontinue breastfeeding at least 90 days before receiving study treatment. They must also refrain from breastfeeding during the course of study and for 90 days after the last dose of study treatment.\n- 29. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.\n- 3. Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study treatment, including but not limited to unstable angina pectoris or acute myocardial infarction, or New York Heart Association Class III or IV cardiac disease, congestive heart failure, and uncontrolled arrhythmia, or other clinically significant heart disease. Participants with a pacemaker and well-controlled rhythm for at least 1 month before the first dose of study treatment are allowed.\n- 30. The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code.\n- 4. History or presence of an ECG abnormality that, in the investigator's opinion, is clinically meaningful. Participants with screening QTcF interval > 470 milliseconds are excluded; in the event that a single QTcF interval measurement is > 470 milliseconds, the participant may enroll if the average QTcF interval length for the 3 ECGs is < 470 milliseconds.\n- 5. For participants assigned to receive PLD only: LVEF below the institutional limit of normal as measured in accordance with local practice guidelines.\n- 6. Known active CNS metastases and/or carcinomatous meningitis. Note: Participants with previously treated and clinically stable brain or CNS metastases (without evidence of progression by imaging for at least 4 weeks before the first dose of study treatment and any neurologic symptoms have returned to baseline), who have no evidence of new or enlarging brain metastasis or CNS edema, and who have not required steroids for at least 7 days before the first dose of study treatment are eligible.\n- 7. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years before the first dose of study treatment. Exceptions include: cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year after treatment with curative intent.\n- 8. Participants with laboratory values at screening defined in Table 7 in the Protocol.\n- 11. For participants assigned to receive paclitaxel only: unresolved > Grade 1 neuropathy.\n- 9. Significant concurrent, uncontrolled medical condition.\n- 31. For participants assigned to receive PLD only: known hypersensitivity to peanuts or soya.\n- 12. History of thromboembolism while on optimal anticoagulation therapy.\n- 13. History of thromboembolism and having been on therapeutic anticoagulation for less than 2 weeks before the first dose of study treatment.\n- 14. Toxic effects of prior therapy and/or complications from prior surgical intervention that have not improved to ≤ Grade 1 before the first dose of study treatment, with the exception of ≤ Grade 2 alopecia and skin hypo-/hyperpigmentation.\n- 15. Prior treatment with any CDK2 inhibitor.\n- 16. Any prior chemotherapy, biological therapy or targeted therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n- 17. Any major surgery within 28 days before the first dose of study treatment."}

Primary endpoints

• {"endpoint_text":"- 1. PFS by BICR, defined as the time from the date of randomization until the earliest date of disease progression as determined by BICR per RECIST v1.1, or death due to any cause, whichever occurs first","definition_or_measurement_approach":"Determined by Blinded Independent Central Review (BICR) per RECIST v1.1; time from randomization to earliest date of disease progression by BICR or death from any cause."}
• {"endpoint_text":"- 2. OS, defined as the time from the date of randomization until death due to any cause.","definition_or_measurement_approach":"Time from randomization until death due to any cause (overall survival)."}

Secondary endpoints

• {"endpoint_text":"- Key Secondary 1. Objective response by BICR, defined as having a best overall response of CR or PR, as determined by BICR per RECIST v1.1.","definition_or_measurement_approach":"Best overall response assessed by BICR per RECIST v1.1; CR or PR counts as objective response."}
• {"endpoint_text":"- Secondary 2. DOR by BICR, defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.","definition_or_measurement_approach":"Duration from first documented CR or PR by BICR until disease progression by BICR or death."}
• {"endpoint_text":"- Secondary 3. PFS by investigator, defined as the time from the date of randomization until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.","definition_or_measurement_approach":"Investigator-assessed PFS per RECIST v1.1; time from randomization to progression by investigator assessment or death."}
• {"endpoint_text":"- Secondary 4. Objective response by investigator, defined as having a best overall response of CR or PR, as determined by investigator assessment per RECIST v1.1.","definition_or_measurement_approach":"Best overall response per investigator assessment using RECIST v1.1 (CR or PR)."}
• {"endpoint_text":"- Secondary 5. DOR by investigator, defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.","definition_or_measurement_approach":"Duration from first documented CR or PR by investigator until progression by investigator assessment or death."}
• {"endpoint_text":"- Secondary 6. AEs, assessed by physical examinations, evaluating changes in vital signs and ECGs, and through clinical laboratory blood sample evaluations.","definition_or_measurement_approach":"Adverse events assessed through clinical evaluation: physical exams, vital signs, ECGs, and laboratory blood tests."}
• {"endpoint_text":"- Secondary 7. Treatment interruptions, dose reductions, and discontinuation of study treatment due to AEs.","definition_or_measurement_approach":"Recording of treatment interruptions, dose reductions and permanent discontinuations attributed to adverse events."}
• {"endpoint_text":"- Secondary 8. HRQoL, assessed by changes from baseline in EORTC QLQ-C30, EORTC QLQ-OV28, and EQ-5D-5L questionnaire scores","definition_or_measurement_approach":"Health-related quality of life measured by change from baseline in EORTC QLQ-C30, QLQ-OV28 and EQ-5D-5L scores."}

Netherlands

Earliest CTIS Part Ii Submission Date

15-04-2026

Latest Decision Or Authorization Date

22-04-2026

Processing Time Days

7

Number Of Sites

5

Number Of Participants

23

Spain

Earliest CTIS Part Ii Submission Date

13-03-2026

Latest Decision Or Authorization Date

21-04-2026

Processing Time Days

39

Number Of Sites

6

Number Of Participants

22

Poland

Earliest CTIS Part Ii Submission Date

30-03-2026

Latest Decision Or Authorization Date

23-04-2026

Processing Time Days

24

Number Of Sites

1

Number Of Participants

20

Belgium

Earliest CTIS Part Ii Submission Date

27-03-2026

Latest Decision Or Authorization Date

17-04-2026

Processing Time Days

21

Number Of Sites

5

Number Of Participants

23

France

Earliest CTIS Part Ii Submission Date

20-03-2026

Latest Decision Or Authorization Date

20-04-2026

Processing Time Days

31

Number Of Sites

9

Number Of Participants

90

Germany

Earliest CTIS Part Ii Submission Date

27-03-2026

Latest Decision Or Authorization Date

20-04-2026

Processing Time Days

24

Number Of Sites

4

Number Of Participants

23

Italy

Earliest CTIS Part Ii Submission Date

20-01-2026

Latest Decision Or Authorization Date

17-04-2026

Processing Time Days

87

Number Of Sites

17

Number Of Participants

85

Ireland

Earliest CTIS Part Ii Submission Date

08-12-2025

Latest Decision Or Authorization Date

15-05-2026

Processing Time Days

159

Number Of Sites

2

Number Of Participants

22

Primary sponsor

Full Name

Incyte Corp.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

Icon Clinical Research Limited

Responsibilities

CRO

Third parties

• {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"CRO","organisation_type":"Pharmaceutical company"}
• {"country":"Netherlands","full_name":"Certe Medische Diagnostiek en Advies Stichting","duties_or_roles":"","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Icon Medical Imaging","duties_or_roles":"Scans/ Imaging","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Agilent Technologies, Inc.","duties_or_roles":"Cyclin E1 testing","organisation_type":"Pharmaceutical company"}
• {"country":"Belgium","full_name":"CellCarta","duties_or_roles":"Central Lab (Cyclin E1 processing)","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"eCoA","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United States","full_name":"Predicine Inc.","duties_or_roles":"","organisation_type":"Hospital/Clinic/Other health care facility"}
• {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"Patient Reimbursement","organisation_type":"Non-Pharmaceutical company"}